Showing results (111-120 of 604) with videos related to

Sort By:
Pageof 61
Pharmacoeconomics - Open|January 13, 2026
Transferable Exclusivity Extension Vouchers for Antimicrobials: Incentive Design, Implementation Challenges, and Policy Trade-OffsMario García-Díaz, Jorge Mestre-Ferrándiz, Jaime Espín
Pharmacoeconomics - Open|November 21, 2025
Model-Based Economic Analyses of Haemophilia from a Societal Perspective: A Scoping ReviewAmr A El-Sayed, Nancy S Bolous
Pharmacoeconomics - Open|June 24, 2025
Including Productivity as an Element to Reflect Value of the Treatment: A Systematic Review of Published Health Economic EvaluationsHiroaki Mamiya, Kittima Wattanakamolkul, Nan Li, et al.
Pharmacoeconomics - Open|October 10, 2025
Carer Health-Related Quality of Life: A Review of Modelling Considerations in National Institute for Health and Care Excellence Technology Appraisals (2000-2023)Charlotte Ahmadu, Elise Evers, Johanna Lister, et al.
Pharmacoeconomics - Open|April 29, 2025
Assessing the Value for Money of Enzyme Replacement Therapy in Gaucher Disease Types 1 and 3b: Can Expanded Coverage Be Justified?Waranya Rattanavipapong, Thunyarat Anothaisintawee, Wanrudee Isaranuwatchai, et al.
Pharmacoeconomics - Open|October 20, 2025
An Introduction to Costing and the Types of Costs Used within Health Economic StudiesHugo C Turner, Juan Carlos Rivillas-Garcia, Shankar Prinja, et al.
Pharmacoeconomics - Open|November 16, 2022
Mapping of the World Health Organization Quality of Life Brief (WHOQOL-BREF) to the EQ-5D-5L in the General Thai PopulationKrittaphas Kangwanrattanakul
Pharmacoeconomics - Open|June 9, 2025
Estimation of Lifetime Costs Among Insured Persons with HIV in the United StatesJoshua P Cohen, Vamshi Ruthwik Anupindi, Riddhi Doshi, et al.
Pharmacoeconomics - Open|June 15, 2023
Mapping the World Health Organization Disability Assessment Schedule (WHODAS 2.0) onto SF-6D Using Swedish General Population DataAnna Philipson, Lars Hagberg, Liselotte Hermansson, et al.
Pharmacoeconomics - Open|March 6, 2026
Cost-Utility Analysis of Faricimab Versus Aflibercept in Treating Neovascular Age-Related Macular Degeneration (nAMD) in the United StatesAhmead Baljoon, Vakaramoko Diaby, Sandra Suther, et al.
Pageof 61